Rapid test for hepatitis B core-related antigen to identify people living with hepatitis B having high viral load in Cameroon

IF 2.4 3区医学 Q3 VIROLOGY Virology Pub Date : 2025-01-01 DOI:10.1016/j.virol.2024.110316

Richard Njouom , Alassane Ndiaye , Abdou Fatawou Modiyinji , Frederic Lissock , Jeanne Perpétue Vincent , Masaya Baba , Naoki Yamamoto , Atsushi Kaneko , Katsumi Aoyagi , Naofumi Hashimoto , Mari Nagai , Masato Ichikawa , Tetsuo Miura , Wataru Sugiura , Yasuhito Tanaka , Yusuke Shimakawa

{"title":"Rapid test for hepatitis B core-related antigen to identify people living with hepatitis B having high viral load in Cameroon","authors":"Richard Njouom , Alassane Ndiaye , Abdou Fatawou Modiyinji , Frederic Lissock , Jeanne Perpétue Vincent , Masaya Baba , Naoki Yamamoto , Atsushi Kaneko , Katsumi Aoyagi , Naofumi Hashimoto , Mari Nagai , Masato Ichikawa , Tetsuo Miura , Wataru Sugiura , Yasuhito Tanaka , Yusuke Shimakawa","doi":"10.1016/j.virol.2024.110316","DOIUrl":null,"url":null,"abstract":"<div><div>This study presents a retrospective assessment of the diagnostic performance of the newly developed hepatitis B core-related antigen rapid diagnostic test (HBcrAg-RDT) in detecting plasma samples with elevated hepatitis B virus (HBV) DNA levels (≥200,000 IU/ml) in Yaoundé, Cameroon. Samples were collected consecutively from treatment-naïve adults living with HBV between January 1, 2021, and June 30, 2023. Analyzing 146 samples from participants with a median age of 36 years, the HBcrAg-RDT exhibited a sensitivity of 97.5% (95% CI: 86.8–99.9) and a specificity of 77.4% (68.2–84.9) when compared to real-time PCR as the reference standard. These findings suggest that HBcrAg-RDT holds promise as a valuable point-of-care tool for diagnosing high HBV DNA levels, particularly in resource-limited settings. Further research will refine its practicality and effectiveness.</div></div>","PeriodicalId":23666,"journal":{"name":"Virology","volume":"602 ","pages":"Article 110316"},"PeriodicalIF":2.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0042682224003404","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This study presents a retrospective assessment of the diagnostic performance of the newly developed hepatitis B core-related antigen rapid diagnostic test (HBcrAg-RDT) in detecting plasma samples with elevated hepatitis B virus (HBV) DNA levels (≥200,000 IU/ml) in Yaoundé, Cameroon. Samples were collected consecutively from treatment-naïve adults living with HBV between January 1, 2021, and June 30, 2023. Analyzing 146 samples from participants with a median age of 36 years, the HBcrAg-RDT exhibited a sensitivity of 97.5% (95% CI: 86.8–99.9) and a specificity of 77.4% (68.2–84.9) when compared to real-time PCR as the reference standard. These findings suggest that HBcrAg-RDT holds promise as a valuable point-of-care tool for diagnosing high HBV DNA levels, particularly in resource-limited settings. Further research will refine its practicality and effectiveness.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在喀麦隆进行乙型肝炎核心相关抗原快速检测，以确定病毒载量高的乙型肝炎患者。

本研究回顾性评估了新开发的乙型肝炎核心相关抗原快速诊断试验（hbrag - rdt）在喀麦隆yaound检测乙型肝炎病毒（HBV） DNA水平升高（≥200,000 IU/ml）血浆样本中的诊断性能。在2021年1月1日至2023年6月30日期间，从treatment-naïve感染HBV的成年人中连续收集样本。与real-time PCR作为参考标准相比，HBcrAg-RDT的灵敏度为97.5% (95% CI: 868 -99.9)，特异性为77.4%（68.2-84.9）。这些发现表明，HBcrAg-RDT有望成为诊断高HBV DNA水平的有价值的护理点工具，特别是在资源有限的环境中。进一步的研究将完善其实用性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Virology 医学-病毒学

CiteScore

6.00

自引率

0.00%

发文量

157

审稿时长

50 days

期刊介绍： Launched in 1955, Virology is a broad and inclusive journal that welcomes submissions on all aspects of virology including plant, animal, microbial and human viruses. The journal publishes basic research as well as pre-clinical and clinical studies of vaccines, anti-viral drugs and their development, anti-viral therapies, and computational studies of virus infections. Any submission that is of broad interest to the community of virologists/vaccinologists and reporting scientifically accurate and valuable research will be considered for publication, including negative findings and multidisciplinary work.Virology is open to reviews, research manuscripts, short communication, registered reports as well as follow-up manuscripts.